What is it about?
To report a case of successful treatment of macrophage activation syndrome complicating adult-onset Still’s disease.
Featured Image
Why is it important?
Macrophage activation syndrome complicating adult-onset Still’s disease carries a high mortality and is often difficult to treat. We treated a patient successfully with a targeted biological agent tocilizumab after a non-selective suppression of the over-active immunity with high dose systemic steroid.
Perspectives
Read the Original
This page is a summary of: Successful treatment of macrophage activation syndrome complicating adult-onset Still’s disease with tocilizumab: a case report, Hong Kong Bulletin on Rheumatic Diseases, December 2017, De Gruyter,
DOI: 10.1515/hkbrd-2017-0011.
You can read the full text:
Contributors
The following have contributed to this page